The FDA recently approved a non-opioid analgesic known as suzetrigine. It has a novel mechanism of action involving selective inhibition of the voltage-gated sodium channel 1.8. This inhibition only reduces peripheral pain signaling pathways as these particular sodium channels are not found in the central nervous system, therefore CNS side-effects such as potential for addiction should not be a concern. 

The potent selectivity for one particular sodium channel is also hoped to result in fewer adverse effects. Longer term studies are still needed to confirm efficacy and safety profiles.
 

Read the FDA notice here.